0.46
0.46 (0%)
As of Feb 14, 2025
Bioatla, Inc. [BCAB]
Source:
Company Overview
Bioatla, Inc. is a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancers. Our conditionally active biologics (“CAB” or “CABs”) capitalize on our proprietary discoveries with respect to tumor biology, enabling us to target known and widely validated tumor antigens that have previously been difficult or impossible to target.
| Country | United States |
| Headquarters | san diego, california |
| Phone Number | ( 858 ) 558-0708 |
| Industry | manufacturing |
| CEO | Jay M. Short, Ph.D. |
| Website | bioatla.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $11 |
| Operating Profit | $-73.9 |
| Net Income | $-69.8 |
| Net Cash | $-62.4 |
Profit Ratios
| Gross Margin | $11 |
| Operating Margin | -672.2 |
| Profit as % of Revenues | -15.8% |
| Profit as % of Assets | -81.1% |
| Profit as % of Stockholder Equity | -489.1% |
Management Effectiveness
| Return on Equity | -489.1% |
| Return on Assets | -133.1% |
| Turnover Ratio | 12.8% |
| EBITA | $-73.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $52.4 |
| Total Liabilities | $38.2 |
| Operating Cash Flow | $-71.9 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $9.5 |
